acquired
Stage
1997
Founded
3
Investors
About
Actelion was a Swiss biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for pulmonary arterial hypertension (PAH) and other rare diseases. It was acquired by Johnson & Johnson in 2017.
Explore Actelion's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.